X4 Pharmaceuticals, Inc (XFOR): M&A transaction — X4 Pharma sells PRV for $105M, draws $20M from Hercules; cash runway extended into late 2025

X4 Pharmaceuticals, Inc

Sold Rare Pediatric Disease Priority Review Voucher for $105M cash; buyer undisclosed.
Drew additional $20M tranche under existing Hercules Capital term loan facility (interest-only until July 2027).
Combined with $82M cash at March 31, 2024, total pro-forma cash ~$207M; runway extended into late 2025, excluding XOLREMDI sales.
CFO Adam Mostafa awarded $102K discretionary bonus for efforts in securing the PRV sale.
XOLREMDI (mavorixafor) received FDA approval in April 2024 for WHIM syndrome; Phase 3 trial in chronic neutropenia planned this quarter.

item 1.01 item 2.01 item 5.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

X4 Pharmaceuticals, Inc completed a disposition for $105.0 million (closed 2024-05-08).

Action: disposition
Consideration: $105.0 million
Closing: 2024-05-08

Exact text from the filing

On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

X4 Pharmaceuticals, Inc entered into Asset Purchase Agreement with not specified valued at $105,000,000 (effective 2024-05-08).

Action: entry
Agreement: asset purchase
Counterparty: not specified
Value: $105,000,000
Effective: 2024-05-08

Exact text from the filing

On May 8, 2024, X4 Pharmaceuticals, Inc. (the “Company”), entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”) for a lump sum payment of $105.0 million, payable in cash upon the closing of the sale, which occurred simultaneously with the parties entering into the Asset Purchase Agreement.

View on SEC.gov

Browse all m&a transactions →

X4 Pharmaceuticals, Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-021937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.